We report the clinical and molecular characteristics of a 69-year-old woman with metastatic colorectal cancer, treated with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody panitumumab, displaying peculiar molecular tumour heterogeneity at progression consisting of KRAS and MET amplification as distinct drivers associated with acquired resistance.
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
SIRAVEGNA, GIULIA;BARDELLI, Alberto;
2016-01-01
Abstract
We report the clinical and molecular characteristics of a 69-year-old woman with metastatic colorectal cancer, treated with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody panitumumab, displaying peculiar molecular tumour heterogeneity at progression consisting of KRAS and MET amplification as distinct drivers associated with acquired resistance.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2016-Clonal evolution and KRAS-MET.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
585.09 kB
Formato
Adobe PDF
|
585.09 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
